Clinical experience with blockade of the renin-angiotensin-aldosterone system by an oral converting-enzyme inhibitor (SQ 14,225, captopril) in hypertensive patients

Progress in Cardiovascular Diseases

Volumn 21, Issue 3, 1978, Pages 195-206

  Case, David B ^a   Atlas, Steven A ^a   Laragh, John H ^a   Sealey, Jean E ^a   Sulivan, Patricia A ^a   McKinstry, Doris N ^a  

^a WEILL CORNELL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN ANTAGONIST; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PLACEBO; SARALASIN; TEPROTIDE;

CARDIOVASCULAR SYSTEM; CLINICAL STUDY; DRUG THERAPY; ENDOCRINE SYSTEM; ESSENTIAL HYPERTENSION; ETIOLOGY; HYPERTENSION; KIDNEY; MAJOR CLINICAL STUDY; PATHOGENESIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RENOVASCULAR HYPERTENSION; THERAPY;

ALDOSTERONE; ALDOSTERONE ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BLOOD PRESSURE; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; HYPERTENSION; POTASSIUM; RENIN; SODIUM; SULFHYDRYL COMPOUNDS;

EID: 0018123212     PISSN: 00330620     EISSN: None     Source Type: Journal    
DOI: 10.1016/0033-0620(78)90025-7     Document Type: Article

References (21)

1. Propranolol inhibition of renin secretion: A specific approach to diagnosis and treatment of renin-dependent hypertensive diseases
2. Proposed mechanism of propranolol's antihypertensive effect in essential hypertension
3. Rapid identification of patients with essential hypertension sensitive to acebutolol (a new cardioselective beta-blocker)
4. Antihypertensive effect of propranolol and spironolactone in relation to plasma angiotensin II
5. Unexpected pressor responses to propranolol in essential hypertension
6. Use of an angiotensin II antagonist (saralasin) in the recognition of “angiotensinogenic” hypertension
7. Hypertension in man: Exposure of the renin and sodium components using angiotensin II blockade
8. Usefulness and limitations of saralasin, a partial competitive agonist of angiotensin II, for evaluating the renin and sodium factors in hypertensive patients
9. Blockade and stimulation of renal, adrenal, and vascular angiotensin II receptors with 1-sar-8-ala-angiotensin II in normal man
10. Possible role of renin in hypertension as suggested by renin-sodium profiling and inhibition of converting enzyme
11. Design of specific inhibitors of angiotensin-converting enzyme: New class of orally active antihypertensive agents
12. A specific orally active inhibitor of angiotensin-converting enzyme in man
13. Inhibition of angiotensin converting enzyme by SQ 14225 in conscious rabbits
14. The human plasma kallikrein-kinin system
15. Antihypertensive effect of the oral angiotensin converting enzyme inhibitor SQ 14225 in man
16. Renin, angiotensin, aldosterone system in pathogenesis and management of hypertensive vascular disease
17. How to do a plasma renin assay
18. Radioimmunoassay of plasma aldosterone
19. Simplified radioimmunoassay of serum aldosterone utilizing increased antibody specificity
20. Aldosterone excretion: Physiologic variations in man measured by radioimmunoassay or double isotope dilution
21. Beta-adrenergic blockade in hypertension: Practical and theoretic implications of long term hemodynamic variations